Last reviewed · How we verify

Uveitis — Treatment Landscape & Competitive Intelligence

Uveitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Uveitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lotemax LOTEPREDNOL ETABONATE Bausch Health Corticosteroid Glucocorticoid receptor 1998-01-01
Flarex FLUOROMETHOLONE ACETATE Harrow Health Corticosteroid Glucocorticoid receptor 1986-01-01
Vantobra Tobramycin Sulfate Pfizer tobramycin Taste receptor type 2 member 20 1974-01-01
Fml FLUOROMETHOLONE AbbVie Corticosteroid Glucocorticoid receptor 1972-01-01
Medrifar MEDRYSONE AbbVie Corticosteroid Glucocorticoid receptor 1969-01-01
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Cortisporin NEOMYCIN Pfizer Aminoglycoside Antibacterial Transient receptor potential cation channel subfamily V member 1 1957-01-01
Cortisporin POLYMYXIN B Pfizer Polymyxin-class Antibacterial 1957-01-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 5 drugs in Uveitis
  2. Pfizer · 4 drugs in Uveitis
  3. AbbVie · 2 drugs in Uveitis
  4. Generic (originally Merck/Upjohn) · 1 drug in Uveitis
  5. Generic (originally Schering) · 1 drug in Uveitis
  6. Hannover Medical School · 1 drug in Uveitis
  7. Harrow Health · 1 drug in Uveitis
  8. Merck & Co. · 1 drug in Uveitis
  9. Novartis · 1 drug in Uveitis
  10. Tufts Medical Center · 1 drug in Uveitis
  11. University Hospital, Angers · 1 drug in Uveitis
  12. University Hospital, Lille · 1 drug in Uveitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Uveitis:

Cite this brief

Drug Landscape (2026). Uveitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/uveitis. Accessed 2026-06-09.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing